Seventeen patients with polycystic ovarian disease (PCOD) and evidence of mild or severe ovarian hyperstimulation syndrome (OHSS) during therapy with CC/hCG, FSH/hCG or hMG/hCG were treated with D-Trp6-LHRH until medical gonadectomy was attained. Under the suppressive therapy with the GnRH agonist (GnRHa) ovulation was induced with FSH/hCG. In 15 out of 17 patients, ovulatory cycles were obtained with this new modality of treatment. Seven patients conceived (3 viable pregnancies and 4 early abortions) after the 1st treatment cycle. Fourteen of the 17 patients demonstrated symptoms of mild OHSS which did not require hospitalization. Only 1 patient developed severe OHSS after the combined treatment. Our results suggest that therapy with GnRHa, especially in its delayed release formulation, is effective for the prevention of severe ovarian hyperstimulation in PCOD patients undergoing treatment with menotropins for the induction of ovulation.

Download full-text PDF

Source
http://dx.doi.org/10.3109/09513598809107655DOI Listing

Publication Analysis

Top Keywords

induction ovulation
8
patients polycystic
8
polycystic ovarian
8
ovarian disease
8
severe ovarian
8
ovarian hyperstimulation
8
patients
6
ovulation d-trp6-lhrh
4
d-trp6-lhrh combined
4
combined purified
4

Similar Publications

Infertility has emerged as a significant global health concern. Assisted reproductive technology (ART) assists numerous infertile couples in conceiving, yet some experience repeated, unsuccessful cycles. This study aims to identify the pivotal clinical factors influencing the success of fresh embryo transfer of in vitro fertilization (IVF).

View Article and Find Full Text PDF

Background: Growth hormone (GH) could improve the outcomes of fertilization and embryo transfer (IVF-ET) in patients with decreased ovarian reserve (DOR), but which age group will benefit the most has remained controversial. This study aims to explore the outcome of IVF-ET among differently aged patients with DOR treated with GH.

Methods: A total of 846 patients with DOR undergoing IVF-ET from May 2018 to June 2023 at the Reproductive Medicine Center of Sichuan Provincial Women's and Children's Hospital were prospectively enrolled.

View Article and Find Full Text PDF

We investigated whether microalgae or linseed supply during the early postpartum period affects ovarian restimulation and supports the first postpartum ovulation in lactating anovulatory goats. Thirty-eight An-glo-Nubian-crossbred adult goats were allocated into three groups, one with a control diet ( = 12), fed a total mixed ration (TMR) comprising chopped elephant grass and concentrate; an algal diet ( = 13), fed TMR + green microalgae (1% dry matter); and a linseed diet ( = 13), TMR + linseed (12% dry matter). Supplements were furnished from the second to fifth week (time of weaning).

View Article and Find Full Text PDF

Role of Glucagon-Like Peptide-1 Receptor Agonists in People With Infertility and Pregnancy.

Obstet Gynecol

January 2025

Department of Obstetrics and Gynecology and the Division of Maternal Fetal Medicine, University of Kansas School of Medicine, Kansas City, Kansas.

Obesity is a chronic condition that causes significant morbidity and mortality in people in the United States and around the world. Traditional means of weight loss include diet, exercise, behavioral modifications, and surgery. New weight loss medications, glucagon-like peptide-1 receptor agonists, are revolutionizing the management of weight loss but have implications for fertility and pregnancy.

View Article and Find Full Text PDF

Triggering final follicular maturation for IVF cycles.

Reprod Biol Endocrinol

January 2025

Infertility and IVF Unit, Department of Obstetrics and Gynecology, Chaim Sheba Medical Center (Tel Hashomer), Ramat Gan, 52621, Israel.

As part of a conventional controlled ovarian hyperstimulation (COH) regimen, final follicular maturation is usually triggered by a single bolus dose of human chorionic gonadotropin (hCG). COH, which combines GnRH antagonist co-treatment with GnRH agonist(GnRHa) trigger, is often used in attempts to eliminate severe early ovarian hyperstimulation syndrome and to improve oocyte/embryo yield and quality. Recently, the combination of GnRHa, with hCG trigger has also been implemented into clinical practice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!